Last reviewed · How we verify

NCT07104513: RLRL

Efficacy and Influencing Factors of Repeated Low-level Red-light in Myopia

Active, enrolled Last updated 8 September 2025
What this trial tests

trial testing Red Light in Myopia in 3,000 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
28 September 2020
Primary endpoint
28 July 2028
28 July 2030

Quick facts

Lead sponsorRuihua Wei
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment3,000
Start date28 September 2020
Primary completion28 July 2028
Estimated completion28 July 2030
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Ruihua Wei — full company profile →

Who can join

Adults 5 to 16, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the long-term efficacy of repeated low-level red-light (RLRL) therapy in the prevention and control of myopia in children, and to analyze the key factors influencing its efficacy (such as individual differences and compliance), with the aim of providing evidence-based support for the optimization of clinical myopia prevention and control strategies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Red Light

Trials testing the same drug.

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Ruihua Wei trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07104513.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing